Comparison of the potency of 10 different brands of Serenoa repens extracts

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 5, 2012, Pages 569-574

  Scaglione, Francesco ^a   Lucini, V ^a   Pannacci, M ^a   Dugnani, S ^a   Leone, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

5a reductase; Benign prostatic hyperplasia; Fibroblasts; Serenoa repens

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; BELTRAX UNO; PERMICAPS; PROSTADYN; PROSTAGUTT; PROSTAMEN; PROSTAMOL UNO; PROSTAX; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; UNCLASSIFIED DRUG; UROCAPS; UROGUTT; FIBROBLAST GROWTH FACTOR; PLANT EXTRACT; PROSTASAN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR;

CELL CULTURE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EPITHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; ARTICLE; COCULTURE; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; STANDARD;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; 5-ALPHA REDUCTASE INHIBITORS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; HUMANS; MALE; PLANT EXTRACTS; PROSTATE; PROSTATIC HYPERPLASIA;

EID: 84864089129     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. http://www.ars-grin.gov/cgibin/npgs/html/taxon.pl?103108.
2. http://www.biomedicine.com/itemDetail.cfml?id=98
3. ZONA S. The genera of Palmae (Arecaceae) in the southeastern United States. Harvard Pap Bot 1997; 2: 71-107.
4. BAYNE CW, DONNELLY F, CHAPMAN K, BOLLINA P, BUCK C, HABIB F. A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5alpha-reductase. J Clin Endocrinol Metab 1998; 83: 206-213.
5. TSUGAYA M, HABIB FK, CHISHOLM GD, ROSS M, TOZAWA K, HAYASHI Y, KOHRI K, TANAKA S. Testosterone metabolism in primary cultures of epithelial cells and stroma from benign prostatic hyperplasia. Urol Res 1996; 24: 265-271.
6. HABIB FK. Regulation of prostate growth in culture with the pollen extract cernitin T-60 and the impact of the drug on the EGF tissue profiles. In: Vahlensick W, Rutishauser G, eds. Benign Prostate Diseases, pp. 120-128. Thieme Verlag, Stuttgart & New York, 1992.
7. BAYNE CW, DONNEL LY F, ROS S M, HABIB FK. Serenoa repens (Permixon®): A 5alpha-reductase types I and II inhibitor - new evidence in a co-culture model of BPH. Prostate 1999; 40: 232-241.
8. SMITH CM, BALLARD SA, WORMAN N, BUETTNER R, MASTERS JR. 5Alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab 1996; 81: 1361-1366.
9. SCAGLIONE F, LUCINI V, PANNACCI M, CARONNO A, LEONE C. Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacol 2008; 82: 270-275.
10. HABIB FK, WYLLIE MG. Not all brands are created equal: A comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004; 7: 195-200.
11. RAYNAUD JP, COUSSE H, MARTIN PM. Inhibition of type 1 and type 2 5 alpha-reductase activity by free fatty acids, active ingredients of Permixon®. J Steroid Biochem Mol Biol 2002; 82: 233-239.
12. WILT T, ISHANI A, MAC DONALD R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002; (3): CD001423.
13. CARRARO JC, RAYNAUD JP, KOCH G, CHISHOLM GD, DI SILVERIO F, TEILLAC P, DA SILVA FC, CAUQUIL J, CHOPIN DK, HAMDY FC, HANUS M, HAURI D, KALINTERIS A, MARENCAK J, PÉRIER A, PERRIN P. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate 1996; 29: 231-240.
14. DEBRUYNE F, KOCH G, BOYLE P, DA SILVA FC, GILLENWATER JG, HAMDY FC, PERRIN P, TEILLAC P, VELA-NAVARRETE R, RAYNAUD JP. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur Urol 2002; 41: 497-507.
15. LOEW D, KASZKIN M. Approaching the problem of bioequivalence of herbal medicinal products. Phytother Res 2002; 16: 705-711.
16. WILT T, ISHANI A. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database System Rev 2002; (1): CD001044.